LumiThera raises $1.15M to advance Valeda photobiomodulation device for dry AMD, in U.S. trials and EU‑approved
LumiThera raised $1.15 million to advance its Valeda Light Delivery System, a photobiomodulation device aimed at improving and slowing vision loss in patients with dry age-related macular degeneration that is in U.S. clinical trials and approved for sale in the EU. The Poulsbo, Washington startup, co‑founded and led by CEO Clark Tedford, lists investors including Keiretsu Forum Northwest and executives with medical-device experience on its leadership team.